Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 4, 1999, Pages 312-318

  Geldof, Albert A ^a   Mastbergen, Simon C ^a   Henrar, Roland E C ^b   Faircloth, Glynn T ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b New Drug Development Office   (Netherlands)

^c PharmaMar USA Inc   (United States)

Author keywords

Aplidine; Cytotoxicity; Didemnin B; Isohomohalichondrin B (IHB); Neurocytotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; DEHYDRODIDEMNIN B; DIDEMNIN B; ISOHOMOHALICHONDRIN B; NAVELBINE; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; HUMAN; HUMAN CELL; NEUROTOXICITY; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DEPSIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; GROWTH INHIBITORS; HUMANS; MALE; NERVOUS SYSTEM DISEASES; OLIGOPEPTIDES; PACLITAXEL; PC12 CELLS; PEPTIDES, CYCLIC; PROSTATIC NEOPLASMS; PYRANS; RATS; SPIRO COMPOUNDS; TUMOR CELLS, CULTURED; VINBLASTINE; VINCRISTINE;

EID: 0032780130     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050983     Document Type: Article

References (29)

1. Bai R, Paull KD, Herald CL, Malpeis L, Pettit GR, Hamel E (1991) Halichondrin B and homohalichondrin B, marine natural products binding to the Vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 266: 15882
2. Capelletti G, Incani C, Maci R (1995) Involvement of tubulin in MPP (+) neurotoxicity on NGF-differentiated PC12 cells. Cell Biol Int 19: 687
3. Faircloth G, Grant W, Nam S, Jimeno J, Manzanares I, Rinehart KL (1998) Preclinical development of aplidine, a novel marine-derived agent with potent antitumor activity. Abstract# 129, 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, 16-19 June 1998, Amsterdam, The Netherlands
4. Ferguson PJ, Cass CE (1985) Differential cellular retention of vincristine and vinblastine by cultured human promyelocytic leukemia hl-60/c1 cells: the basis of differential cytotoxicity. Cancer Res 45: 5480
5. Garcia-Rocha M, Garcia-Gravalos MD, Avila J (1996) Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15. Br J Cancer 73: 875
6. Geldof AA (1995) Nerve-growth-factor-dependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy. J Cancer Res Clin Oncol 121: 657
7. Geldof AA, Rao BR, de Voogt HJ (1986) Direct effects of chemotherapeutic agents on rat prostate tumor clonogenic cells. Anticancer Res 6: 837
8. Geldof AA, Minneboo A, Heimans JJ (1995) Quantification of chemotherapy related neuropathy using an in vitro model (abstract). Anticancer Res 15: 1665
9. Geldof AA, Minneboo A, Heimans JJ (1998) Vinca-alkaloid neurotoxicity measured using an in vitro model. J Neurooncol 37: 109
10. Goss G, Muldal A, Lohmann R, Taylor M, Lopez P, Armitage G, Steward WP (1995) Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 13: 257
11. Hirata Y, Uemura D (1986) Halichondrins: anti-tumor polyether macrolides from a marine sponge. Pure Appl Chem 58: 701
12. Jiang TL, Liu RH, Salmon SE (1983) Antitumor activity of Didemnin B in the human tumor stem cell assay. Cancer Chemother Pharmacol 11: 1
13. Li LH, Timmins LG, Wallace TL, Krueger WC, Prairie MD, Im WB (1984) Mechanism of action of Didemnin B, a depsipeptide from the sea. Cancer Lett 23: 279
14. Lobo C, Garcia-Pozo SG, Nunez de Castro I, Alonso FJ (1997) Effect of dehydrodidemnin B on human colon carcinoma cell lines. Anticancer Res 17: 333
15. Malfetano JH, Blessing JA, Homesley HD, Look KY, McGehee R (1996) A phase II trial of didemnin B (NSC:335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Am J Clin Oncol 19: 184
16. Nuyen B, Henrar REC, Gomez A, Beijnen JH (1998) Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumour agent aplidine (dehydrodidemnin B). Abstract #180, 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, 16-19 June 1998, Amsterdam, The Netherlands
17. Rinehart Jr KL, Gloer JB, Hughes Jr RG, Renis HE, McGovern JP, Swynenberg EB, Stringfellow DA, Kuentzel SL, Li LH (1981) Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate. Science 212: 933
18. Rowinsky EK, Donehauwer DC (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 52: 35
19. Sakai R, Rinehart KL, Kishore V, Kundu B, Faircloth G, Gloer JB, Carney JR, Namikoshi M, Sun F, Hughes RG, Garcia-Grávalos D, de Quesada TG, Wilson GR, Heid RM (1996) Structure-activity relationships of the didemnins. J Med Chem 39: 2819
20. Schiff PB, Horowitz SB (1990) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561
21. Schiff PB, Fant J, Horowitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 22: 665
22. Shin DM, Holoye PY, Murphy WK, Forman A, Papasozomenos SC, Hong WK, Raber M (1991) Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting. Cancer Chemother Pharmacol 29: 145
23. Shin DM, Holoye PY, Forman A, Winn R, Perez-Soler R, Dakhil S, Raber MN, Hong WK (1994) Phase II clinical trial of didemnin B in previously treated small cell lung cancer. Review. Invest New Drugs 12: 243
24. SirDeshpande BV, Toogood PL (1995) Mechanism of protein synthesis inhibition by Didemnin B in vitro. Biochemistry 34: 9177
25. Sondak VK, Kopecky KJ, Liu PY, Fletcher WS, Harvey WH, Laufman LR (1994) Didemnin B in metastatic melanoma: a phase II trial of the Soutwest Oncology Group. Anticancer Drugs 5: 147
26. Toso RJ, Jordan MA, Farrell KW, Matsumto B, Wilson L (1993) Kinetic stabilization of microtubule dynamic stability in vitro by vinblastine. Biochemistry 32: 1285
27. Urdiales JL, Morata P, Nuñez de Castro I, Sanchez-Jimenez F (1996) Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 102: 31
28. Weiss RB, Peterson BL, Allen SL, Browning SM, Duggan DB, Schiffer CA (1994) A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALG-B) study. Invest New Drugs 12: 41
29. Williamson SK, Wolf MK, Eisenberger MA, O'Rourke M, Brannon W, Crawford ED (1995) Phase II evaluation of Didemnin B in harmonally refractory metastatic prostate cancer. A South West Oncology Group Study. Invest New Drugs 13: 167